ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » (1827–1839) Fibromyalgia & Other Clinical Pain Syndromes Poster

Date: Tuesday, November 14, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM
Abstract Number: 1835
A Survey on Fibromyalgia-Related Knowledge Among Internal Medicine Residents
9:00AM-11:00AM
Abstract Number: 1829
Blood-derived Extracellular Vesicles as Potential Diagnostic Biomarker in Fibromyalgia Syndrome
9:00AM-11:00AM
Abstract Number: 1837
Depression and Suicide Attempt in Systemic Lupus Erythematosus with and Without Fibromyalgia
9:00AM-11:00AM
Abstract Number: 1833
Development of a Polygenic Risk Model for Therapeutic Response to Bedtime Sublingual Cyclobenzaprine (TNX-102 SL*) in Fibromyalgia Based on Polygenic Single Nucleotide Polymorphism (SNP)-Count Scores
9:00AM-11:00AM
Abstract Number: 1831
Effect of the COVID-19 Pandemic on Health Status of Fibromyalgia
9:00AM-11:00AM
Abstract Number: 1836
Embracing a Biopsychosocial Approach to Fibromyalgia-like Symptoms in People with SLE: Insights from the Type 2 SLE Consortium
9:00AM-11:00AM
Abstract Number: 1834
Evaluation of Fibromyalgia, Clinical/Serologic Activity, and Patient Reported Outcomes in a Racially/Ethnically Diverse SLE Patient Cohort
9:00AM-11:00AM
Abstract Number: 1830
Exploring Psychosocial Characteristics of Youth with Chronic Pain Across Gender Identities
9:00AM-11:00AM
Abstract Number: 1828
Positive Screening for Fibromyalgia or Depression on Validated MDHAQ Indices Is Seen in 56-71% of Rheumatoid Arthritis Patients with High DAS28 or CDAI, 40-47% with Moderate, 2-42% with Low, and 0-21% with DAS28 or CDAI Remission
9:00AM-11:00AM
Abstract Number: 1832
Prevalence of Musculoskeletal Manifestations in Post-acute COVID 19 Patients and Their Quality of Life at Kenyatta National Hospital
9:00AM-11:00AM
Abstract Number: 1827
Revolutionizing Fibromyalgia Treatment: Exploring the Efficacy of a New FDA Cleared Photoceutical Device
9:00AM-11:00AM
Abstract Number: 1838
The Burden of Dysautonomia in Patients Suffering from Pathologies Associated with Generalized Joint Hypermobility
9:00AM-11:00AM
Abstract Number: 1839
Value of Small Fiber Neuropathy in Fibromyalgia Patients in a Rheumatological Setting

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology